From Promise to Reality: MyoKardia and Medpace Talk Precision Medicine in Cardiovascular Disease, Upcoming Webinar Hosted by Xtalks

Share Article

In this complimentary webinar, featured speakers from Medpace and MyoKardia will discuss precision medicine approaches for treating cardiovascular disease and its growing role in clinical trials. A case study of MyoKardia’s MAVERICK-HCM trial will be presented, highlighting operational challenges, best practices and lessons learned. Future directions, including mitigations during a pandemic will also be disussed.

By matching mechanism of a drug action with specific disease etiology, precision-medicine approaches are starting to turn the page in CVD trials.

Despite advances in medical therapeutics, cardiovascular disease (CVD) remains the leading cause of death worldwide. Notably, heart failure and coronary disease continue to present an exorbitant burden on patients and health care. Recently, breakthroughs in precision medicine are creating optimism for a field that has historically witnessed few long-term successes in targeted therapeutic approaches.

Indeed, precision-medicine approaches target the subsets of patients that are most likely to benefit from a drug, including approaches based on mechanism of disease and shared patient characteristics. By matching mechanism of a drug action with specific disease etiology, precision-medicine approaches are starting to turn the page in CVD trials.

Investigational drugs like mavacamten, developed by MyoKardia, offer new hope for patients with hypertrophic cardiomyopathy (HCM), an inherited and often lethal primary myocardial disorder without effective pharmacological options. Indeed, the striking positive results found in obstructive and non-obstructive HCM patients are expected to support a New Drug Application (NDA) filing, thus commencing a new promising chapter in the precision-medicine approach to CVD drug discovery.

Join experts from Medpace and MyoKardia in a live webinar on Tuesday, December 15, 2020 at 12pm EST (5pm GMT/UK).

For more information, or to register for this event, visit From Promise to Reality: MyoKardia and Medpace Talk Precision Medicine in Cardiovascular Disease.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ayesha Rashid
Xtalks
+1 (416) 977-6555 x 272
Email >
Visit website